Compound C1, an analog of curcumin, could induce ALP activation by directly stimulating TFEB, thereby alleviating Aβ precursor protein (APP) and Tau pathology during the early stages of AD progression in vivo (16). This evidence concerns the gene MAPT and Alzheimer disease.